$11.96
0.08% day before yesterday
Nasdaq, Dec 27, 10:00 pm CET
ISIN
US24661P5008
Symbol
DCTH

Delcath Systems Inc Stock price

$11.96
+0.74 6.60% 1M
+3.73 45.32% 6M
+7.80 187.50% YTD
+7.90 194.58% 1Y
+3.88 48.02% 3Y
-16.81 58.43% 5Y
-2,587,199,988.04 100.00% 10Y
Nasdaq, Closing price Fri, Dec 27 2024
-0.01 0.08%
ISIN
US24661P5008
Symbol
DCTH
Sector

Key metrics

Market capitalization $382.41m
Enterprise Value $371.49m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 16.41
P/S ratio (TTM) P/S ratio 16.89
P/B ratio (TTM) P/B ratio 39.10
Revenue growth (TTM) Revenue growth 945.91%
Revenue (TTM) Revenue $22.64m
EBIT (operating result TTM) EBIT $-26.75m
Free Cash Flow (TTM) Free Cash Flow $-26.20m
Cash position $13.99m
EPS (TTM) EPS $-1.36
P/E forward negative
P/S forward 11.07
EV/Sales forward 10.75
Short interest 4.46%
Show more

Is Delcath Systems Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

Delcath Systems Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Delcath Systems Inc forecast:

7x Buy
100%

Analyst Opinions

7 Analysts have issued a Delcath Systems Inc forecast:

Buy
100%

Financial data from Delcath Systems Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
23 23
943% 943%
100%
- Direct Costs 4.27 4.27
259% 259%
19%
18 18
1,774% 1,774%
81%
- Selling and Administrative Expenses 29 29
62% 62%
129%
- Research and Development Expense 16 16
9% 9%
69%
-26 -26
23% 23%
-117%
- Depreciation and Amortization 0.30 0.30
39% 39%
1%
EBIT (Operating Income) EBIT -27 -27
23% 23%
-118%
Net Profit -34 -34
24% 24%
-151%

In millions USD.

Don't miss a Thing! We will send you all news about Delcath Systems Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Delcath Systems Inc Stock News

Neutral
Business Wire
27 days ago
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced that the U.S. Food and Drug Administration (FDA) has completed its 30-day review of the Company's Investigational New Drug (IND) application for a Phase 2 clinical trial evaluating HEPZATO™ in combination wi...
Positive
Seeking Alpha
about one month ago
Delcath's Q3 US sales hit $10 million. This unlocked $25 million in cash from its Tranche B Warrants, which will fund its Phase 2 trials for mCRC and mBC. HEPZATO KIT's hospital rollout is progressing well. Delcath plans to end the year with 15 centers and end 2025 with 30. Treatment has gone well at UCLA. Three retrospective clinical trials and the FOCUS trial's subgroup analysis add to the gr...
Positive
Seeking Alpha
about one month ago
Delcath Systems' Q3 earnings revealed strong growth with $11.2M in revenue, driven by HEPZATO and CHEMOSAT sales, and an 85% gross margin. The company is expanding its commercial footprint with 12 active treatment centers and plans to reach 30 by the end of 2025. Promising growth drivers include new cancer indications for HEPZATO, potential label expansion, and combining with immune checkpoint ...
More Delcath Systems Inc News

Company Profile

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers. The company's lead product candidate is the melphalan hydrochloride for injection for use with the Delcath hepatic delivery system to administer high-dose chemotherapy to the liver. Its Phase III clinical trial products include FOCUS Trial for the patients with hepatic dominant ocular melanoma; and ALIGN Trial for intrahepatic cholangiocarcinoma. The company also offers melphalan hydrochloride under the Delcath Hepatic CHEMOSAT Delivery System for Melphalan name in Europe. The company was founded in 1988 and is headquartered in New York, New York.

Head office United States
CEO Gerard Michel
Employees 76
Founded 1988
Website www.delcath.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today